Venetoclax plus azacitidine in higher-risk myelodysplastic syndromes: a treatment-purpose framework for interpreting response depth - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating Treatment Outcomes of Venetoclax Combined with Azacitidine in High-Risk Myelodysplastic Syndromes: A Framework for Understanding Response Depth

  • By

  • Xinfu Zou

  • Jinyang Bu

  • Aojiao Chu

  • Ling Shi

  • Zheng Zhang

  • Qin Zheng

  • Meihong Luo

  • August 24, 2026

Share

  • 1

    Venetoclax combined with azacitidine shows substantial clinical activity in treatment-naïve higher-risk myelodysplastic syndromes.

  • 2

    Higher response rates with venetoclax plus azacitidine do not necessarily correlate with improved overall survival in HR-MDS.

  • 3

    A treatment-purpose framework distinguishes between bridging to transplantation and controlling disease without transplantation.

  • 4

    In a study cohort, 39.3% of patients proceeded to transplantation after treatment with venetoclax plus azacitidine.

  • 5

    Venetoclax plus azacitidine should be viewed as a potential bridge to transplantation, not as a guaranteed means to enhance post-transplant survival.

Original Source(s)

Venetoclax plus azacitidine in higher-risk myelodysplastic syndromes: a treatment-purpose framework for interpreting response depth

  • by Xinfu Zou, Jinyang Bu, Aojiao Chu, Ling Shi, Zheng Zhang, Qin Zheng, Meihong Luo

  • August 24, 2026

Related Content

Commentary: Impact of HPV vaccine on CIN2+ recurrence after conization: a systematic review and meta-analysis of vaccination timing, valency and surgical margins

Correction: Deep learning accurately and reliably segments pelvic vascular structure in CT scans of gynecologic cancer patients

Transitioning from hand-sewn to circular stapled cervical anastomosis after minimally invasive esophagectomy: a Western centre propensity score matching analysis